We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

119 hedge funds and large institutions have $424M invested in Keryx Biopharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $6.38M | Put options by funds: $3.8M

24% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 29

11% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 18

6% more capital invested

Capital invested by funds: $399M → $424M (+$25.1M)

3% less funds holding

Funds holding: 123 → 119 (-4)

Holders
119
Holders Change
-4
Holders Change %
-3.25%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
36
Reduced
29
Closed
18
Calls
$6.38M
Puts
$3.8M
Net Calls
+$2.59M
Net Calls Change
+$3.89M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$29.6M
2
CLM
ClearBridge LLC (Maryland)
Maryland
+$7.14M
3
OWIM
Old West Investment Management
California
+$3.39M
4
State Street
State Street
Massachusetts
+$3.19M
5
Millennium Management
Millennium Management
New York
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$7.57M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.57M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$2.49M
4
QIM
Quantitative Investment Management
Virginia
-$1.17M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$159M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$42.2M +$1.66M +302,986 +5%
ACM
3
Abrams Capital Management
Massachusetts
$35.2M – – –
BlackRock
4
BlackRock
New York
$33.4M +$29.6M +5,408,594 +80,282%
State Street
5
State Street
Massachusetts
$21.4M +$3.19M +582,624 +20%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$14.3M -$852K -155,500 -6%
Norges Bank
7
Norges Bank
Norway
$10.5M – – –
Ameriprise
8
Ameriprise
Minnesota
$10.1M -$1.02M -185,288 -10%
RHJA
9
Rice Hall James & Associates
California
$8.26M +$217K +39,656 +3%
CLM
10
ClearBridge LLC (Maryland)
Maryland
$8.02M +$7.14M +1,302,640 New
Millennium Management
11
Millennium Management
New York
$7.85M +$2.29M +417,186 +49%
Northern Trust
12
Northern Trust
Illinois
$6.28M +$341K +62,298 +7%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$5.73M -$2.49M -455,019 -33%
OWIM
14
Old West Investment Management
California
$5.11M +$3.39M +619,285 +295%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.98M +$319K +58,270 +8%
Goldman Sachs
16
Goldman Sachs
New York
$4.18M +$123K +22,388 +3%
Charles Schwab
17
Charles Schwab
California
$2.69M +$142K +25,842 +6%
Morgan Stanley
18
Morgan Stanley
New York
$2.66M -$142K -25,919 -6%
RPAM
19
Rhenman & Partners Asset Management
Sweden
$2.62M – – –
Boston Partners
20
Boston Partners
Massachusetts
$2.52M – – –
IAM
21
Iridian Asset Management
Connecticut
$1.63M +$200K +36,540 +16%
UBS Group
22
UBS Group
Switzerland
$1.63M +$156K +28,416 +12%
RA
23
Royce & Associates
New York
$1.58M – – –
TCIM
24
TIAA CREF Investment Management
New York
$1.31M -$79.6K -14,526 -6%
KCM
25
Knoll Capital Management
Florida
$1.23M – – –
1
2 3 4 5

KERX Hedge Fund Activity: Q1 2017 in Review

119 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q1 2017, worth a combined $424M — up 6.3% from $399M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new KERX positions and 18 closed out — a net gain of 2 holders — while 36 added to existing stakes and 29 trimmed.

The largest buyer was BlackRock, adding an estimated $29.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $7.57M sold.

  • 119 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q1 2017, down from 123 in Q4 2016.
  • Funds reported $424M of Keryx Biopharmaceuticals Inc stock for Q1 2017, up 6.3% quarter-over-quarter.
  • 20 funds opened new Keryx Biopharmaceuticals Inc positions in Q1 2017 and 18 closed out, a net change of +2 holders.
  • The largest Keryx Biopharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $29.6M added.
  • The largest Keryx Biopharmaceuticals Inc seller in Q1 2017 was Deerfield Management, an estimated $7.57M sold.

Based on aggregated 13F filings for Q1 2017.